Advertisement

Topics

FDA Says 'No' to Resubmission of Anti Arrhythmic Drug

06:15 EDT 22 Aug 2017 | PharmPro

Cardiome provides U.S. regulatory update for Brinavess. The FDA indicated that data supplied was not compelling enough to support a resubmission of the company's New Drug Application, despite acceptance elsewhere around the world.
Contributed Author: 
Cardiome Pharma Corp.
Topics: 

Original Article: FDA Says 'No' to Resubmission of Anti Arrhythmic Drug

NEXT ARTICLE

More From BioPortfolio on "FDA Says 'No' to Resubmission of Anti Arrhythmic Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...